Xtl Biopharmaceuticals (XTLB) Revenue (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted Revenue of $289000.0 for Q4 2024, down 71.94% sequentially from $1.0 million in Q3 2018.

Xtl Biopharmaceuticals (XTLB) Revenue (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals has reported Revenue for 7 years, with the latest figure at $289000.0 in Q4 2024.

Quarterly Revenue changed N/A year-over-year to $289000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.2 million (changed N/A YoY) and the FY2025 annual result came in at -$549000.0, down 221.73% from the prior year.
Revenue fell to $289000.0 in Q4 2024 per XTLB's latest filing, from $1.0 million in the prior quarter.
Over five years, Revenue peaked at $289000.0 in Q4 2024 and troughed at $289000.0 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Xtl Biopharmaceuticals	2.64 Bn	2.64 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	289,000.00
Sep 30, 2018	1.03 Mn
Jun 30, 2018	34,000.00
Mar 31, 2018	875,000.00
Sep 30, 2017	-1.59 Mn
Jun 30, 2017	1.39 Mn
Mar 31, 2017	977,000.00
Sep 30, 2014	287,000.00
Jun 30, 2014	380,000.00
Mar 31, 2014	587,000.00
Dec 31, 2013	711,000.00
Sep 30, 2013	473,000.00
Jun 30, 2013	512,000.00
Mar 31, 2013	673,000.00
Dec 31, 2012	595,000.00
Sep 30, 2012	343,000.00
Jun 30, 2012	559,000.00
Mar 31, 2012	645,000.00
Dec 31, 2011	734,000.00
Sep 30, 2011	529,000.00